EX-99.1
2
dex991.htm
PRESS RELEASE
Press Release
Exhibit 99.1
Press / Investor Contact
:
Bonnie Ortega
Director, Investor/Public Relations
Cardium Therapeutics, Inc.
Tel: (858) 436-1018
Email: InvestorRelations@cardiumthx.com
CARDIUM COMPLETES SALE OF INNERCOOL THERAPIES BUSINESS
TO ROYAL PHILIPS ELECTRONICS
SAN DIEGO, Calif. - July 24, 2009 - Cardium Therapeutics (NYSE Amex: CXM) ("Cardium") today announced that it has completed the asset sale of Cardium's InnerCool Therapies business ("InnerCool") to
Royal Philips Electronics (NYSE: PHG, AEX: PHI). The asset purchase transaction was for $11.25 million, as well as the transfer of approximately $1.5 million in trade payables.
About Royal Philips Electronics
Royal Philips Electronics of the Netherlands (NYSE: PHG, AEX:
PHI) is a diversified Health and Well-being company, focused on improving people's lives through timely innovations. As a world leader in healthcare, lifestyle and lighting, Philips integrates technologies and design into people-centric
solutions, based on fundamental customer insights and the brand promise of "sense and simplicity". Headquartered in the Netherlands, Philips employs approximately 116,000 employees in more than 60 countries worldwide. With sales of EUR 26
billion in 2008, the company is a market leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as lifestyle products for personal well-being and pleasure with strong
leadership positions in flat TV, male shaving and grooming, portable entertainment and oral healthcare. News from Philips is located at www.philips.com/newscenter.
About Cardium
Cardium is focused on the acquisition and strategic development of new and innovative bio-medical
product opportunities and businesses that have the potential to address significant unmet medical needs and definable pathways to commercialization, partnering and other economic monetization's. Cardium's initial investment portfolio
includes InnerCool Therapies, Inc., the Tissue Repair Company, and Cardium Biologics, medical technology companies primarily focused on the development, manufacture and sale of innovative therapeutic products and devices for cardiovascular, ischemic
and related indications. News from Cardium is located at www.cardiumthx.com.
Forward-Looking Statements
Except for statements of historical fact, the matters discussed in this press release are forward-looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our
control and may cause actual results to differ materially from stated expectations. Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our
operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development, testing and marketing of biologic product candidates and the conduct of human clinical trials, including the timing,
costs and outcomes of such trials, our dependence upon proprietary technology, our ability to obtain necessary funding, regulatory approvals and qualifications, our history of operating losses and accumulated deficits, our reliance on collaborative
relationships and critical personnel, and current and future competition, as well as other risks described from time to time in filings we make with the Securities and Exchange Commission. We undertake no obligation to release publicly the results
of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.
Copyright 2009
Cardium Therapeutics, Inc. All rights reserved.
For Terms of Use Privacy Policy, please visit www.cardiumthx.com.
Cardium Therapeutics™ and Generx™ are trademarks of Cardium Therapeutics, Inc.
Tissue Repair™, Gene Activated Matrix™, GAM™ and Excellarate™
are trademarks of Tissue Repair Company.
InnerCool Therapies
®
, InnerCool
®
, Celsius Control
System
®
, RapidBlue™, CoolBlue™. Accutrol
®
,
Temperature Control
Element
®
and TCE
®
and UroCool
™ a
re trademarks of InnerCool Therapies, Inc.
(other trademarks belong to their respective owners)

EX - 99 . 1 2 dex991 . htm PRESS RELEASE Press Release Exhibit 99 . 1 Press / Investor Contact : Bonnie Ortega Director , Investor / Public Relations Cardium Therapeutics , Inc . Tel : ( 858 ) 436 - 1018 Email : InvestorRelations@cardiumthx.com CARDIUM COMPLETES SALE OF INNERCOOL THERAPIES BUSINESS TO ROYAL PHILIPS ELECTRONICS SAN DIEGO , Calif . - July 24 , 2009 - Cardium Therapeutics ( NYSE Amex : CXM ) ( " Cardium " ) today announced that it has completed the asset sale of Cardium 's InnerCool Therapies business ( " InnerCool " ) to Royal Philips Electronics ( NYSE : PHG , AEX : PHI ) . The asset purchase transaction was for $ 11.25 million , as well as the transfer of approximately $ 1.5 million in trade payables . About Royal Philips Electronics Royal Philips Electronics of the Netherlands ( NYSE : PHG , AEX : PHI ) is a diversified Health and Well - being company , focused on improving people 's lives through timely innovations . As a world leader in healthcare , lifestyle and lighting , Philips integrates technologies and design into people - centric solutions , based on fundamental customer insights and the brand promise of " sense and simplicity " . Headquartered in the Netherlands , Philips employs approximately 116,000 employees in more than 60 countries worldwide . With sales of EUR 26 billion in 2008 , the company is a market leader in cardiac care , acute care and home healthcare , energy efficient lighting solutions and new lighting applications , as well as lifestyle products for personal well - being and pleasure with strong leadership positions in flat TV , male shaving and grooming , portable entertainment and oral healthcare . News from Philips is located at www.philips.com/newscenter . About Cardium Cardium is focused on the acquisition and strategic development of new and innovative bio - medical product opportunities and businesses that have the potential to address significant unmet medical needs and definable pathways to commercialization , partnering and other economic monetization 's . Cardium 's initial investment portfolio includes InnerCool Therapies , Inc . , the Tissue Repair Company , and Cardium Biologics , medical technology companies primarily focused on the development , manufacture and sale of innovative therapeutic products and devices for cardiovascular , ischemic and related indications . News from Cardium is located at www.cardiumthx.com . Forward - Looking Statements Except for statements of historical fact , the matters discussed in this press release are forward - looking and reflect numerous assumptions and involve a variety of risks and uncertainties , many of which are beyond our control and may cause actual results to differ materially from stated expectations . Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment , including , without limitation , risks and uncertainties that are inherent in the development , testing and marketing of biologic product candidates and the conduct of human clinical trials , including the timing , costs and outcomes of such trials , our dependence upon proprietary technology , our ability to obtain necessary funding , regulatory approvals and qualifications , our history of operating losses and accumulated deficits , our reliance on collaborative relationships and critical personnel , and current and future competition , as well as other risks described from time to time in filings we make with the Securities and Exchange Commission . We undertake no obligation to release publicly the results of any revisions to these forward - looking statements to reflect events or circumstances arising after the date hereof . Copyright 2009 Cardium Therapeutics , Inc . All rights reserved . For Terms of Use Privacy Policy , please visit www.cardiumthx.com . Cardium Therapeutics ™ and Generx ™ are trademarks of Cardium Therapeutics , Inc . Tissue Repair ™ , Gene Activated Matrix ™ , GAM ™ and Excellarate ™ are trademarks of Tissue Repair Company . InnerCool Therapies ® , InnerCool ® , Celsius Control System ® , RapidBlue ™ , CoolBlue ™ . Accutrol ® , Temperature Control Element ® and TCE ® and UroCool ™ a re trademarks of InnerCool Therapies , Inc . ( other trademarks belong to their respective owners )